METHODS FOR MODULATING MONOCYTE FUNCTION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 27, 2015
filing date -
Oct 27, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
It has been discovered that HSP90 inhibitors can inhibit both the pro-inflammatory and pro-coagulatory potential of monocytes, in particular activated monocytes. One embodiment provides a method of inhibiting the pro-inflammatory phenotype of monocytes, preferably in human subjects, most preferably in human subjects having Sickle Cell Disease (SCD). A preferred HSP90 inhibitor is 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide (NVP-AUY922).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully